Recent studies have demonstrated that the primary mechanism of anti-tumor activity associated with PD-1/PD-L1 inhibitors involves PD-1+ TCF-1+ stem-like CD8+ T cells, specifically the exhausted CD8+ T cells (Tpex). Here, CD274 is linked to neoplasm.